First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Core Insights - Immutep Limited has successfully dosed the first patient in its pivotal TACTI-004 Phase III trial, evaluating eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer [1][6] Company Overview - Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 to stimulate or suppress immune responses [8] Trial Details - TACTI-004 is a randomized, double-blind, controlled Phase III study enrolling approximately 756 patients across over 150 clinical sites in more than 25 countries, targeting advanced or metastatic non-small cell lung cancer without specific genomic aberrations [5][7] - The trial's dual primary endpoints are progression-free survival and overall survival, with recruitment currently underway [7] Market Context - Lung cancer is the leading cause of cancer-related deaths, with an expected increase to approximately 3 million cases globally by 2030, and non-small cell lung cancer (NSCLC) accounts for about 80-85% of all lung cancer diagnoses [3] - There is a significant unmet need for new treatment options in NSCLC, as less than 30% of patients survive five years post-diagnosis [3]